Prelude Therapeutics (PRLD) Cash from Operations (2019 - 2026)

Prelude Therapeutics has disclosed Cash from Operations across 8 years of filings, most recently posting 21685000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 21685000.0, up 36.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 43756000.0 (up 58.46% YoY), and the FY2025 annual result was 56302000.0, up 45.28% from the prior year.
• Cash from Operations came in at 21685000.0 for Q1 2026 at Prelude Therapeutics, down from 23119000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 23119000.0 in Q4 2025 to a low of 34231000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 23057000.0 (2024), against an average of 21862764.71.
• Across the five-year window, Cash from Operations sank 49.82% in 2023 and surged 211.45% in 2025, its largest moves.
• Prelude Therapeutics' Cash from Operations stood at 22927000.0 in 2022, then dropped by 2.84% to 23578000.0 in 2023, then rose by 12.02% to 20744000.0 in 2024, then soared by 211.45% to 23119000.0 in 2025, then sank by 193.8% to 21685000.0 in 2026.
• The last three Cash from Operations figures came in at 21685000.0 (Q1 2026), 23119000.0 (Q4 2025), and 19115000.0 (Q3 2025), per Business Quant data.